Inclusion Criteria:

          1. Female aged 18 - 65 years old;

          2. Staging of Cancer: cT1-2N0-1M0;

          3. Histological confirmed with unilateral invasive carcinoma (all pathological types are
             applicable);

          4. Definite reports on ER/PR/Her2 receptor showing all ER/PR/Her2 negative (specific
             definitions: immunohistochemical detection of ER <10% tumor cells is defined as ER
             negative, PR <10% positive tumor cells is defined as PR-negative, Her2 is 0~1+ or 2+
             but determined negative via FISH or CISH detected (no amplification) is defined as
             Her2 negative);

          5. Newly diagnosed conditions allowing direct surgery without any absolute
             contraindication for surgery;

          6. ECOG performance score is 0 or 1;

          7. No mass or microscopic tumor residue after surgery resection;

          8. Informed consent form signed.

          9. Willing to return to enrolling institution for follow-up during the Active Monitoring
             Phase (the active treatment and observation portions) of the study.

        Exclusion Criteria:

          1. Bilateral breast cancer;

          2. Clinical or radiographic evidence of metastatic disease;

          3. Widespread disease that cannot be incorporated by local excision through a single
             incision that achieves negative margins with a satisfactory cosmetic result;

          4. Diffuse suspicious or malignant-appearing microcalcifications;

          5. Positive pathologic margin;

          6. Any of ER, PR or Her2 is positive;

          7. Previous neoadjuvant therapy, including chemotherapy, radiotherapy and hormone
             therapy;

          8. Prior history of breast cancer or any other malignant disease (except for basal cell
             carcinoma and cervical carcinoma in situ);

          9. Severe systemic disease and/or uncontrollable infection, unable to be enrolled in this
             study;

         10. Known allergic to taxane and anthracycline agents;

         11. Pregnant and breast-feeding women;

         12. With mental illness and cognitive impairment, unable to understand trial protocol and
             side effects and complete trial protocol and follow-ups;

         13. Without personal freedom and independent civil capacity.